) vaccines division, Sanofi Pasteur, announced that the European
Commission (EC) has approved its 6-in-1 pediatric vaccine
The vaccine will be marketed as Hexyon in Western European
countries (including France, Germany, and UK among others), while
it will be marketed as Hexacima in Eastern European countries.
The 6-in-1 vaccine will prevent diphtheria, tetanus, pertussis
(whooping cough), hepatitis B, poliomyelitis and invasive
infections caused by haemophilus influenzaetype b in infants.
The approval did not come as a surprise as the European Medicines
Agency's (EMA) Committee for Medicinal Products for Human Use
(CHMP) rendered a positive opinion on Hexyon/Hexacima in Feb
The approval came on the basis of data from phase III studies,
which enrolled approximately 5,000 infants. Hexyon/Hexacima
demonstrated encouraging efficacy and safety profile in the
We note that Sanofi possesses one of the world's leading vaccine
operations, with total sales of €3.9 billion in 2012. The
company's portfolio includes pediatric vaccines, influenza
vaccines, adult and adolescent booster vaccines, meningitis
vaccines, and travel and endemic vaccines. Sanofi also has a
strong position in both seasonal and pre-pandemic influenza
Sanofi continues to expand its vaccine business. We expect a
significant ramp in vaccine sales over the next several years.
Sanofi carries a Zacks Rank #3 (Hold) in the short run.
Meanwhile, stocks such as
Transcept Pharmaceuticals, Inc.
Osiris Therapeutics, Inc.
) carry a Zacks Rank #1 (Strong Buy) and are worth
ATHERSYS INC (ATHX): Free Stock Analysis
OSIRIS THERAPTC (OSIR): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
TRANSCEPT PHARM (TSPT): Get Free Report
To read this article on Zacks.com click here.